Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | NMT2 | O60551 | 2/20 | 0.43 |
| ▸ | NMT1 | P30419 | 2/20 | 0.43 |
| ▸ | FURIN | P09958 | 7/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402921 | 0.97 | TLR2 (0.48) | TLR2NMT2NMT1FURINSIRT6 | |
| SCHEMBL13402932 | 0.95 | NMT2 (0.44) | TLR2NMT2NMT1FURINSIRT2 | |
| SCHEMBL13402935 | 0.94 | NMT2 (0.43) | TLR2NMT2NMT1FURINSIRT2 | |
| SCHEMBL13402927 | 0.93 | NMT2 (0.45) | TLR2NMT2NMT1FURINSIRT2 | |
| SCHEMBL13402926 | 0.90 | NMT2 (0.45) | TLR2NMT2NMT1FURINSIRT2 | |
| SCHEMBL13402931 | 0.84 | FURIN (0.49) | FURIN | |
| SCHEMBL10168670 | 0.83 | NMT2 (0.44) | TLR2NMT2NMT1SIRT2SIRT5 | |
| SCHEMBL23868502 | 0.82 | GNPAT (0.41) | TLR2NMT2NMT1FURINSIRT6 | |
| SCHEMBL13402924 | 0.81 | FURIN (0.52) | FURIN | |
| SCHEMBL13402947 | 0.81 | GNPAT (0.47) | SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105567-A1 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | SHARP KABUSHIKI KAISHA (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20090312192-A1 | METHOD FOR FUNCTIONALISING A HYDROPHOBIC SUBSTRATE | SHARP KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090192048-A1 | METHOD OF PRODUCING A MULTIMERIC CAPTURE AGENT FOR BINDING A LIGAND | SHARP KABUSHIKI KAISHA (JP) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105567-A1 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | MST1R, CCL2, DNPEP | TLR2 1429/4885NMT2 289/4885NMT1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.